LTIP702A - A slimming pharmaceutical composition - Google Patents

A slimming pharmaceutical composition

Info

Publication number
LTIP702A
LTIP702A LTIP702A LTIP702A LTIP702A LT IP702 A LTIP702 A LT IP702A LT IP702 A LTIP702 A LT IP702A LT IP702 A LTIP702 A LT IP702A LT IP702 A LTIP702 A LT IP702A
Authority
LT
Lithuania
Prior art keywords
pharmaceutical composition
ephedrine
human
reducing
slimming
Prior art date
Application number
LTIP702A
Inventor
Arne Astrup
Original Assignee
Dak Lab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dak Lab As filed Critical Dak Lab As
Publication of LTIP702A publication Critical patent/LTIP702A/en
Publication of LT3536B publication Critical patent/LT3536B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to a method for reducing the weight of a human and a method for reducing the adipose tissue mass/lean mass body mass ratio of a human or a domestic animal. In each method, an effective dose of a combination of ephedrine and caffeine are administered in a weight ratio of about 1:12, respectively, calculated on the amount of ephedrine in the form of the free base.
LTIP702A 1989-07-07 1993-06-23 A slimming pharmaceutical composition LT3536B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK339289A DK339289D0 (en) 1989-07-07 1989-07-07 PHARMACEUTICAL PREPARATION

Publications (2)

Publication Number Publication Date
LTIP702A true LTIP702A (en) 1995-01-31
LT3536B LT3536B (en) 1995-11-27

Family

ID=8122369

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP702A LT3536B (en) 1989-07-07 1993-06-23 A slimming pharmaceutical composition

Country Status (18)

Country Link
US (1) US5422352A (en)
EP (1) EP0480934B1 (en)
JP (1) JP2584899B2 (en)
KR (1) KR0159045B1 (en)
AT (1) ATE107858T1 (en)
AU (1) AU638992B2 (en)
CA (1) CA2063598C (en)
DE (1) DE69010336T2 (en)
DK (2) DK339289D0 (en)
ES (1) ES2055911T3 (en)
FI (1) FI920026A0 (en)
HU (1) HU220071B (en)
LT (1) LT3536B (en)
LV (1) LV10192B (en)
NO (1) NO920051L (en)
RU (1) RU2109511C1 (en)
UA (1) UA27779C2 (en)
WO (1) WO1991000730A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5865869A (en) * 1991-08-02 1999-02-02 Ecologel Usa, Inc. Solution for plant root watering
AU4659793A (en) * 1992-06-30 1994-01-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Anorectic epinephrine derivatives
WO1994008609A1 (en) * 1992-10-15 1994-04-28 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION
ES2094687B1 (en) * 1994-08-02 1997-12-16 S A L V A T Lab Sa PHARMACEUTICAL COMBINATION AGAINST OBESITY OR OVERWEIGHT.
FR2746644A1 (en) * 1996-03-18 1997-10-03 Firion Jackie APPETITE MODERATOR PARAPHARMACEUTICAL PRODUCT
US6224873B1 (en) 1996-09-30 2001-05-01 Zhishin, Llc Regulation of appetite, body weight and athletic function with materials derived from citrus varieties
DE69638106D1 (en) * 1996-09-30 2010-02-11 Dennis Jones Regulation of body weight by materials based on citrus variations
AU728889C (en) 1996-12-23 2001-08-02 S.L.A. Pharma Ag Pharmaceutical composition for treating fecal incontinence and anal itch
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
HUP9700654A2 (en) 1997-03-26 1999-09-28 Dezső Korbonits Antitussive compositions containing theobromine
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6277402B1 (en) 1998-06-26 2001-08-21 Delack Elaine Alice Method for treatment of multiple sclerosis and related disease states
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6340482B1 (en) * 2000-05-18 2002-01-22 Zhishin, Llc Methods for inducing weight loss in a human with materials derived from Citrus varieties
US6113949A (en) * 1998-10-27 2000-09-05 Prolab Nutrition, Inc. Weight control product and method of treating hyperlipidemia and increasing vigor with said product
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
FR2788438B1 (en) * 1999-01-14 2003-10-03 Arkopharma Laboratoires COMPOSITION FOR THE TREATMENT OF OBESITY AND AESTHETIC TREATMENT METHOD
US6576272B1 (en) * 1999-03-05 2003-06-10 Twin Laboratories Incorporated Dietary supplement and method of using same
WO2001005356A2 (en) * 1999-07-20 2001-01-25 Natrol, Inc. Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant
MXPA02001882A (en) * 1999-08-23 2002-08-20 Univ Tulane Modulation of the blood brain barrier transporter for leptin.
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
DE10011541A1 (en) * 2000-03-06 2001-09-20 Reimann Hartmut Water additive for increasing vitality of bony fish, comprising combination of ephedrine and caffeine and/or theophylline, especially useful for combating transport stress
US6316499B1 (en) 2000-05-18 2001-11-13 Zhishin, Llc Methods for increasing the muscle mass of a human with materials derived from citrus varieties
KR20030005204A (en) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 Sympathetic-activating perfume composition
US7048941B2 (en) * 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
US7041305B2 (en) * 2001-09-07 2006-05-09 Western Holdings, Llc Stable water in oil aminophylline emulsions
RU2209582C2 (en) * 2001-10-22 2003-08-10 Горелик Самуил Лейбович Method for controlling patient's body weight
GB0130763D0 (en) 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
AU2003224507A1 (en) * 2002-04-19 2003-11-03 N.V. Nutricia Multiphasic diet
US8142810B2 (en) * 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
US20040077530A1 (en) * 2002-10-18 2004-04-22 Robert Portman Composition for reducing caloric intake
US20040224031A1 (en) * 2003-05-06 2004-11-11 Antonio Zorzano Olarte Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
EP2250911A1 (en) 2003-10-17 2010-11-17 Diet Formulations Ltd. Weight-loss supplement
AU2004292416B2 (en) * 2003-11-20 2010-01-28 Alteragon Pty Ltd Method of decreasing fat deposits and body weight in mammals and birds
PL209905B1 (en) * 2004-01-15 2011-11-30 Bringwell Internat Ab Formulation for treating obesity and associated metabolic syndrome
CA2455248A1 (en) * 2004-01-29 2005-07-29 Alexander Zolotoy Oral administration of r-albuterol against obesity
US7524064B2 (en) * 2004-03-09 2009-04-28 Research Foundation Of The State University Of New York Apparatus and method for assessing retinal damage
US20060074057A1 (en) * 2004-10-04 2006-04-06 Eric Marchewitz Use of chenodeoxycholic acid for reducing adipose tissue
US20060134230A1 (en) * 2004-12-17 2006-06-22 Sal Abraham Weight loss composition and formulation
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US9610429B2 (en) * 2010-12-29 2017-04-04 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue with targeted substance delivery
NZ706326A (en) 2012-10-08 2018-01-26 Rivalea (Australia) Pty Ltd Animal feed supplement comprising ractopamine and caffeine
US9877434B2 (en) 2013-05-30 2018-01-30 Ecologel Solutions, Llc Granular compositions and methods for drought mitigation
BR112016022039A2 (en) * 2014-03-26 2017-08-15 Rivalea Australia Pty Ltd METHOD TO IMPROVE FEEDING EFFICIENCY IN RUMINANTS
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
AU2016219070B2 (en) 2015-02-13 2020-06-11 Mars, Incorporated Pet food feeding system
WO2016167855A1 (en) * 2015-04-14 2016-10-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination of albuterol and caffeine as synergistic treatment for obesity or sarcopenia
GB201522296D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product to reduce body fat
WO2020232424A1 (en) 2019-05-16 2020-11-19 Nexus Pharmaceuticals, Inc. Compositions comprising ephedrine or an ephedrine salt and methods of making and using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2390164A1 (en) * 1977-05-13 1978-12-08 Blanie Paul Anti:asthmatic methyl-xanthine compsns. - synergised with beta-sympathomimetic agents
NL7710582A (en) 1977-06-03 1978-12-05 Pharmaceutical Export Promotio PROCESS FOR PREPARING A SLIMMING PREPARATION.
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors

Also Published As

Publication number Publication date
HU220071B (en) 2001-10-28
JP2584899B2 (en) 1997-02-26
CA2063598A1 (en) 1991-01-08
KR0159045B1 (en) 1998-12-01
CA2063598C (en) 1997-12-09
AU638992B2 (en) 1993-07-15
HK1001821A1 (en) 1998-07-10
UA27779C2 (en) 2000-10-16
EP0480934B1 (en) 1994-06-29
US5422352A (en) 1995-06-06
HUT62798A (en) 1993-06-28
NO920051D0 (en) 1992-01-03
EP0480934A1 (en) 1992-04-22
LV10192A (en) 1994-10-20
ATE107858T1 (en) 1994-07-15
NO920051L (en) 1992-01-31
DE69010336D1 (en) 1994-08-04
DK0480934T3 (en) 1994-11-07
AU5630890A (en) 1991-02-06
FI920026A7 (en) 1992-01-03
LV10192B (en) 1995-06-20
HU9200051D0 (en) 1992-06-29
WO1991000730A1 (en) 1991-01-24
DK339289D0 (en) 1989-07-07
RU2109511C1 (en) 1998-04-27
LT3536B (en) 1995-11-27
FI920026A0 (en) 1992-01-03
ES2055911T3 (en) 1994-09-01
DE69010336T2 (en) 1994-11-03
JPH04507091A (en) 1992-12-10

Similar Documents

Publication Publication Date Title
LTIP702A (en) A slimming pharmaceutical composition
EP0552256A4 (en)
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE239482T1 (en) NEW MEDICINAL FORMULATION
YU47543B (en) PROCEDURE FOR OBTAINING PHARMACEUTICAL PREPARATION FOR GRANULLocyte Stimulation
NO169291C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TETRAPYRROL-AMINO-DICARBOXYLIC ACID ADD
PT977564E (en) FORCOLINA FOR THE PROMOTION OF BODY MASS MAGRA
MY109309A (en) Improvements in or relating to somatostatins
NZ333724A (en) Enhancing lean tissue mass and bone mineral content by the administration of calcium compositions
HU883863D0 (en) Process for the preparation of producing and/or portionly form of therapeutical agents
BE898749A (en) NEW PROCESS FOR THE PREPARATION OF GALENIC FORMS USEFUL IN PARTICULAR IN THERAPEUTICS, DIETETICS, COSMETICS AND DIAGNOSIS
GR1002802B (en) Cosmetic compositions and skin treatment compositions
EP0214254A1 (en) Melatonin compositions and uses thereof.
EP0813409A4 (en) Treatment of cytokine growth factor caused disorders
IL92180A (en) Pharmaceutical composition for preventing or reducing eosinophilia
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
IL101675A (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
GB2004183A (en) Compositions containing caffeine and ephedrine or their derivatives
UA41326C2 (en) Pharmaceutical composition for prevention or treatment of viral diseases, means for prevention or treatment of viral diseases
KR900017599A (en) Pharmaceutical composition for tumor treatment
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
IT1200350B (en) FOOTREST SUPPORT FOR THE HUMAN BODY IN THE PRACTICE OF THE WHIRLPOOL ADAPTABLE TO THE BOTTOM
IE780730L (en) Veterinary composition
IT1263754B (en) Pharmaceutical composition for treatment of localised adiposity and cellulite

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20060623